Pancreatic ductal adenocarcinoma, commonly abbreviated as PDAC, is the most common form of pancreatic cancer, accounting for roughly 90% of all pancreatic malignancies. It is among the deadliest cancers in the world, with five-year survival rates in the single digits for metastatic disease and a biology that makes it extraordinarily resistant to most treatments. The combination of late detection, a uniquely hostile tumor environment, and limited drug options has made PDAC one of the most active areas of cancer research, though progress has been slower than with many other tumor types.
Where PDAC Comes From
The name “ductal” is somewhat misleading. For decades, researchers assumed PDAC originated in the cells lining the pancreatic ducts, the tiny tubes that carry digestive enzymes from the pancreas to the small intestine. More recent work has shown that the cancer often begins in acinar cells, the enzyme-producing cells of the pancreas, which first undergo a transformation into duct-like cells before progressing through precancerous stages called PanINs and eventually into full-blown PDAC.1PubMed Central. Cell of Origin of Pancreatic cancer Novel Findings and Current Understanding Mouse studies confirm that both ductal and acinar cells can give rise to PDAC under certain genetic conditions, though the cell of origin appears to influence how the tumor behaves and what it looks like under a microscope.2Gut. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma
Genetically, PDAC is dominated by a handful of recurring mutations. The KRAS gene is mutated in the vast majority of cases, acting as the primary driver that pushes cells toward uncontrolled growth. Three major tumor suppressor genes are frequently knocked out as well: TP53, CDKN2A, and SMAD4, each of which normally acts as a brake on cell division or a safeguard against DNA damage.3PubMed Central. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer When all four of these genetic safeguards fail in the same cell, the result is a highly aggressive tumor with a strong tendency to invade surrounding tissues and spread to distant organs.
The Fortress Around the Tumor
One of the most distinctive features of PDAC is what researchers call desmoplasia: a dense, scar-like reaction that surrounds and permeates the tumor. In many PDAC tumors, this fibrous stroma actually makes up more of the tumor mass than the cancer cells themselves.4PubMed Central. Desmoplasia and therapeutic resistance in pancreatic ductal adenocarcinoma Think of it as the tumor building a fortress around itself. The dense matrix squeezes blood vessels shut, which starves the interior of oxygen and creates a high-pressure environment where drugs simply cannot penetrate effectively.
This is a major reason why PDAC responds so poorly to chemotherapy compared with many other cancers. The physical barrier blocks drug delivery, while the low-oxygen environment triggers survival pathways in the tumor cells that help them withstand whatever drug does manage to reach them. Cancer-associated fibroblasts, cells that the tumor recruits and reprograms, maintain this barrier and also suppress immune responses, creating a microenvironment where the immune system cannot do its job.5PubMed. Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia PDAC is widely considered an immunologically “cold” tumor, meaning it fails to attract or support the immune T cells that patrol for and destroy cancer. Even in early-stage PDAC, the T cells found within the tumor tend to be exhausted or effectively blind to the cancer’s presence.
Causes and Risk Factors
PDAC risk factors fall into two broad camps: things you can change and things you cannot. On the modifiable side, smoking is the most well-established environmental risk factor, and heavy alcohol consumption compounds that risk. Obesity, particularly fat accumulated around the midsection, increases PDAC risk through chronic low-grade inflammation and insulin resistance.6PubMed Central. Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss Chronic pancreatitis, the long-term inflammation of the pancreas that often results from years of heavy drinking, is another significant risk factor. More recently, researchers have flagged high consumption of refined sugar and sugar-sweetened beverages as associated with increased risk, especially in younger people, and exposure to certain heavy metals and industrial chemicals has been linked to higher rates as well.7PubMed. The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC
On the hereditary side, several genetic syndromes raise PDAC risk substantially. These include hereditary breast and ovarian cancer syndrome (linked to BRCA mutations), Lynch syndrome, familial atypical multiple mole melanoma syndrome, Peutz-Jeghers syndrome, hereditary pancreatitis, and cystic fibrosis.8PubMed Central. Epidemiology and risk factors of pancreatic cancer Whole-genome sequencing of families with multiple cases of pancreatic cancer has identified genes like PALB2 as susceptibility genes. In one landmark study, researchers sequenced a patient with familial pancreatic cancer and found a truncating mutation in PALB2; further screening of 96 additional familial patients turned up three more distinct protein-truncating mutations in the same gene.9PubMed Central. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene
Why Symptoms Appear Late
PDAC is notorious for being nearly silent in its early stages. The pancreas sits deep in the abdomen, behind the stomach, and tumors can grow for months without pressing on anything that would cause noticeable symptoms. When symptoms do appear, they depend on where the tumor is located. Cancers in the head of the pancreas (the part closest to the small intestine) tend to cause jaundice, the yellowing of the skin and eyes that occurs when the tumor blocks the bile duct. Cancers in the body or tail of the pancreas, however, may produce nothing more than vague upper abdominal pain or back pain until they are quite advanced.10PubMed Central. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies
Other common symptoms include unexplained weight loss, loss of appetite, nausea, fatty or greasy stools (from the pancreas failing to produce enough digestive enzymes), and a general feeling of fatigue. None of these are specific to pancreatic cancer, which is part of why so many patients are diagnosed only after the disease has already spread.
New-Onset Diabetes as a Warning Sign
One of the more intriguing clues that something may be wrong with the pancreas is the sudden onset of diabetes in someone over 50 who has no typical risk factors for it. Older patients who develop diabetes for the first time have roughly eight times the risk of harboring pancreatic cancer compared with the general population.11PubMed Central. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer The tumor appears to disrupt the pancreas’s ability to regulate blood sugar before it causes any of the classic cancer symptoms. Recognizing this pattern could, in theory, catch PDAC at a stage when surgery is still an option.
Researchers are actively building large cohorts of patients over 50 with new-onset diabetes to study this connection more rigorously and to develop blood-based biomarkers that could distinguish cancer-related diabetes from ordinary type 2 diabetes.12PubMed Central. A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer The challenge is enormous: new-onset diabetes is common, and pancreatic cancer is relatively rare, so any screening approach needs to be very good at filtering out false alarms. But the potential payoff, catching PDAC before symptoms and before metastasis, is worth the effort.
Diagnosis and Biomarkers
When PDAC is suspected, the workup usually starts with imaging. CT scans with contrast are the standard first step, and endoscopic ultrasound (EUS) provides more detailed pictures of the pancreas and can guide a needle biopsy for tissue confirmation. CA 19-9, a protein shed into the blood by many pancreatic tumors, is the most commonly used blood biomarker. It is not sensitive enough to serve as a screening test in healthy people, but it is useful for tracking disease progression and assessing whether a tumor is likely resectable. In one prospective study, a CA 19-9 level above 1,000 U/mL predicted unresectability with accuracy comparable to CT and EUS.13Gastrointestinal endoscopy. CA 19-9 level as a criterion of unresectability in pancreatic cancer: A prospective comparison with CT and EUS Combining CA 19-9 with EUS findings in a diagnostic model has shown even better accuracy for identifying malignancy, particularly in patients who also have chronic pancreatitis, where distinguishing cancer from inflammation is especially tricky.14Pancreas. Combination of Serum CA 19-9 and Endoscopic Ultrasound Findings Can Predict Malignancy Risk in Patients With Chronic Pancreatitis Presenting With Pancreatic Head Mass
A newer frontier is liquid biopsy, the analysis of tumor-derived material circulating in the blood. This can include fragments of tumor DNA, circulating tumor cells, or tiny membrane-bound particles called extracellular vesicles. The appeal is clear: a simple blood draw that could detect cancer early, track treatment response, and guide therapy selection without repeated tissue biopsies. For PDAC specifically, research into liquid biopsies has intensified, though the technology has not yet matured enough for routine clinical use.15PubMed. Liquid biopsy in pancreatic cancer – Current perspective and future outlook
Surgery
Surgery is the only treatment that offers a realistic chance of long-term survival, but only about 15 to 20% of patients are candidates for it at the time of diagnosis. Most patients present with disease that has already invaded major blood vessels or spread to distant organs, putting them beyond what surgery can address. For tumors in the head of the pancreas, the standard operation is the Whipple procedure, a complex surgery that removes the head of the pancreas, a portion of the small intestine, the gallbladder, and part of the bile duct. For tumors in the body or tail, a distal pancreatectomy removes the affected portion along with the spleen.16PubMed Central. The role of surgery for pancreatic cancer: a 12-year review of patient outcome
There is growing evidence that giving chemotherapy before surgery (called neoadjuvant therapy) rather than only afterward improves outcomes. A meta-analysis of studies comparing the two approaches found that patients who received neoadjuvant therapy had a lower risk of death, better disease-free survival, lower rates of positive lymph nodes, and a higher rate of achieving clean surgical margins.17PubMed Central. Neo-Adjuvant Treatment in Primary Resectable Pancreatic Cancer: A Systematic Review and PRISMA-Compliant Updated Metanalysis of Oncological Outcomes Pre-surgical treatment can shrink the tumor, making the operation easier, and it tests whether the cancer responds to chemotherapy. If it does not, the patient may be spared a major surgery that was unlikely to help.
Chemotherapy Regimens
For patients with metastatic PDAC who are well enough to tolerate aggressive treatment, the two main chemotherapy regimens are FOLFIRINOX (a four-drug combination) and gemcitabine plus nab-paclitaxel. Head-to-head comparisons in large real-world populations have consistently favored FOLFIRINOX. In one study of over 1,100 patients, those receiving FOLFIRINOX had a weighted median overall survival of about 9.6 months compared with about 6.1 months for gemcitabine plus nab-paclitaxel, along with fewer emergency visits and hospitalizations.18PubMed Central. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis A separate large comparison found a similar survival advantage, with median survival of about 9.3 months for FOLFIRINOX versus 6.9 months for the gemcitabine regimen, and FOLFIRINOX was also associated with fewer post-treatment hospitalizations and lower costs.19JAMA Network Open. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
The trade-off is toxicity. FOLFIRINOX causes more febrile neutropenia, a dangerous drop in infection-fighting white blood cells that requires hospitalization. Real-world data showed that febrile neutropenia-related hospitalizations were roughly twice as common with FOLFIRINOX.18PubMed Central. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis For older patients, those with poor performance status, or those with other serious health conditions, gemcitabine-based regimens remain the safer and more practical choice. Neither regimen is curative for metastatic disease, but extending survival by even a few months can be meaningful.
Targeted and Precision Therapies
For most of its history, PDAC has been resistant to the kinds of targeted therapies that have transformed treatment for other cancers. That picture is beginning to change, though slowly. A few established precision approaches now exist. Patients whose tumors carry BRCA1 or BRCA2 mutations and who respond to platinum-based chemotherapy can receive maintenance therapy with olaparib, a PARP inhibitor that exploits the tumor’s inability to repair DNA damage. For the small fraction of patients whose tumors are mismatch repair-deficient, immune checkpoint inhibitors can produce durable responses. And in the rare cases where NTRK gene fusions are present, drugs targeting the resulting abnormal protein have shown activity.20PubMed Central. Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
The most exciting development may be the emerging ability to target KRAS directly. KRAS was long considered “undruggable” because of its smooth, featureless surface. The first breakthrough came with inhibitors of the KRAS G12C mutation, which is relatively uncommon in pancreatic cancer but proved the concept that KRAS could be hit. Agents targeting the far more common KRAS G12D mutation are now in early clinical trials and showing encouraging results.20PubMed Central. Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges Preclinical work has shown that combining a KRAS G12D inhibitor with a PARP inhibitor produces strong synergy in PDAC models, reducing tumor volume more than either drug alone and suppressing the tumor’s DNA repair machinery.21Nature Communications. Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC
PARP inhibitor use may extend beyond patients with BRCA or PALB2 mutations. In a single-institution study, patients with other DNA repair gene mutations (such as ATM, CHEK2, and RAD51C) who received maintenance PARP inhibitors showed that over half achieved stable disease for more than four months.22PubMed Central. PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience This is preliminary, but it suggests the eligible population for this class of drugs could be wider than initially thought.
Cachexia and Weight Loss
One of the most debilitating aspects of PDAC is cachexia, a severe wasting syndrome that goes well beyond ordinary weight loss from not eating enough. Cachexia affects an estimated 70 to 80% of pancreatic cancer patients and involves the involuntary loss of both muscle and fat tissue, driven by the tumor itself.23PubMed Central. Pancreatic Cancer and Cachexia-Metabolic Mechanisms and Novel Insights The cancer releases signaling molecules that ramp up inflammation throughout the body, reprogram metabolism, and directly trigger muscle breakdown. In mouse studies, a protein called PAUF, secreted by pancreatic cancer cells, caused significant muscle wasting even when administered directly to muscle tissue in the absence of a tumor, and a neutralizing antibody against PAUF was able to reverse this effect.24PubMed Central. Pancreatic cancer induces muscle wasting by promoting the release of pancreatic adenocarcinoma upregulated factor
Cachexia is increasingly understood as a systemic multi-organ problem, not just a matter of losing muscle. It drives anorexia, disrupts the gut microbiome, impairs heart function, and causes both the exocrine (digestive enzyme) and endocrine (insulin-producing) functions of the pancreas to fail.25hLife. Pancreatic cancer cachexia: A systemic consequence of multi-organ interactions The exocrine insufficiency is especially relevant because it worsens malnutrition: without enough digestive enzymes, patients cannot absorb fats and fat-soluble vitamins from food. Pancreatic enzyme replacement therapy is a standard part of supportive care, and it has been shown to improve quality of life. In patients with unresectable PDAC, the degree of exocrine insufficiency is actually an independent predictor of survival, making enzyme supplementation more than just a comfort measure.26ESMO Open. Management of pancreatic exocrine insufficiency in pancreatic cancer: a consensus review and practical guidance
Where PDAC Spreads
The liver is PDAC’s preferred destination for metastasis. The pancreas drains directly into the portal venous system that feeds the liver, giving tumor cells a direct highway. Research has identified molecular mechanisms behind this preference: proteins involved in cell-to-cell adhesion, particularly E-cadherin and p120-catenin, appear to influence whether cancer cells settle in the liver or get redirected to the lungs. In mouse models, loss of one copy of the p120-catenin gene dramatically shifted the pattern of spread from liver-dominant to lung-dominant metastasis.27Developmental Cell. P120-Catenin and E-Cadherin Synergize to Control Pancreatic Cancer Progression and Metastatic Organotropism Beyond the liver and lungs, PDAC can spread to the lining of the abdominal cavity (the peritoneum), and less frequently to bone and other sites.
The Microbiome Connection
An emerging and somewhat surprising line of research has found that bacteria are present inside pancreatic tumors themselves, and the composition of the gut and intratumoral microbiome appears to influence PDAC risk, tumor progression, and how well patients respond to treatment.28PubMed Central. The role of microbiome in pancreatic cancer The pancreas was long considered essentially sterile, so finding bacterial communities inside pancreatic tumors upended assumptions. It remains unclear whether these bacteria arrive via the bile duct, through the bloodstream, or by another route. What is increasingly clear is that they interact with the tumor microenvironment and may modulate immune responses within it.29PubMed Central. The Role of the Microbiome in Pancreatic Cancer This is early-stage science, but it opens the possibility that manipulating the microbiome through antibiotics, probiotics, or fecal transplants could eventually become part of a treatment strategy.
Disparities in Treatment and Outcomes
Not everyone with PDAC receives the same standard of care, and the gaps are troubling. Studies in the United States have consistently found that African American patients and those who are uninsured or underinsured receive less aggressive treatment, are less likely to undergo surgery, and experience delayed treatment compared with white patients and those with private insurance.30PubMed Central. Disparities in Pancreatic Cancer Treatment and Outcomes Private insurance has been associated with a higher likelihood of receiving any treatment at all, along with better survival, while African American patients in national datasets have been found to have lower treatment rates and greater treatment delays even after accounting for disease stage.31Pancreas. Racial and Socioeconomic Disparities in the Treatments and Outcomes of Pancreatic Cancer Among Different Treatment Facility Types Higher education levels were linked to earlier initiation of treatment. These disparities persist across different types of treatment facilities and are not fully explained by biological differences in tumor behavior, pointing instead to systemic issues of access, referral patterns, and the geographic distribution of high-volume surgical centers.32PubMed Central. Racial and socioeconomic disparities in surgical management and outcomes in pancreatic adenocarcinoma: a single-center experience in the last 13 years
In a cancer where timing and access to specialized surgery matter enormously, these gaps translate directly into survival differences. Getting to a high-volume pancreatic surgery center, having insurance that covers multi-drug chemotherapy regimens, and being referred promptly to oncology all influence whether a patient reaches the small window where curative treatment is possible.